NOVARTIS AG CEDEAR EAC 4 REP 1(USD) revenue breakdown overview

NOVARTIS AG CEDEAR EAC 4 REP 1(USD) revenue for the last year amounted to 50.32 B USD, the most of which — 14.29 B USD — came from its highest performing source at the moment, Oncology, the year earlier bringing 14.51 B USD. The greatest contribution to the revenue figure was made by United States — last year it brought NOVARTIS AG CEDEAR EAC 4 REP 1(USD) 20.50 B USD, and the year before that — 19.17 B USD.